Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business product launch

Bracco Imaging launches BubbleGen CD3+ kit

Analysis based on 6 articles · First reported Sep 09, 2026 · Last updated Sep 09, 2026

Sentiment
10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The launch of the BubbleGen CD3+ T Cell Selection Kit could strengthen Bracco S.p.A. — Bracco Imaging's position in the cell therapy manufacturing market by offering a novel bead-free alternative. This may positively impact Bracco's revenue prospects in the growing cell therapy sector, though the immediate market impact is limited as the product is for research use only.

Biotechnology Pharmaceuticals Medical devices

Bracco S.p.A. — Bracco Imaging, a global pharmaceutical company, announced the expansion of its BubbleGen cell selection portfolio with the launch of the BubbleGen CD3+ T Cell Selection Kit. The kit, built on Bracco's microbubble technology, enables magnetic bead-free cell selection for cell therapy research and development, including a scalable and cost-effective approach to manufacturing CAR-T cell therapies. This is the first of multiple planned expansions following the launch of an early access program in May 2026. The technology uses antibody-targeted lipid microbubbles that selectively bind desired cell populations and then dissipate, eliminating magnetic iron residuals and column-related cell loss. The kit is designed for CD3+ T-cell isolation and supports applications such as T cell isolation, depletion, CAR-T and TCR-T development, and process development workflows. It is compatible with automated and closed manufacturing systems and is expected to be available for clinical use in 2027. The kit is now available for research use, and Bracco will introduce it at the CAR-TCR Summit in Boston on September 16-17, 2026.

subs
Bracco S.p.A. — Bracco Imaging is the developer and launcher of the BubbleGen CD3+ T Cell Selection Kit, expanding its product portfolio in cell therapy manufacturing. This launch could enhance its competitive position and future revenue streams.
Importance 100.0 Sentiment 20.0
priv
Bracco Group is the parent company of Bracco S.p.A. — Bracco Imaging and stands to benefit from the successful commercialization of the BubbleGen technology, reinforcing its leadership in diagnostic imaging and expanding into cell therapy.
Importance 80.0 Sentiment 20.0
per
Sophie He, VP of Cell Therapy at Bracco S.p.A. — Bracco Imaging, is a spokesperson for the launch, articulating the strategic importance of the BubbleGen portfolio expansion. Her role is supportive and does not directly affect the company's market position.
Importance 30.0 Sentiment 0.0
per
Thierry Bettinger, R&D Director at Bracco Research Center Geneva, contributed to the development of the BubbleGen technology and is quoted in the announcement. His role is technical and supportive.
Importance 30.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.